Axiom, a U.S. biotech firm, is opting for a Hong Kong listing ahead of a U.S. debut, highlighting a shift in the funding landscape for biotech companies.
According to Remo Moomiaie-Qajar, Axiom's CEO, the U.S. biotech funding model has not evolved alongside the industry's needs, prompting firms to explore alternative markets. He noted that recent biotech listings in Hong Kong have outperformed those on the Nasdaq, suggesting a more mature ecosystem in that region. The Hong Kong exchange's stricter listing standards may also contribute to this perception of stability and growth.
The increasing costs of clinical trials and a shrinking pool of venture capitalists willing to invest in later-stage companies have made public markets a more attractive option for biotech firms. The Hang Seng Biotech Index has seen significant growth, outperforming its U.S. counterparts, which reflects a rising interest in Hong Kong as a biotech fundraising hub. The city has recently streamlined its IPO process, making it easier for companies to enter the market.
Despite these advantages, local investors in Hong Kong tend to favor companies with connections to China, indicating a preference for partnerships that facilitate co-development and manufacturing. This trend underscores the importance of strategic alliances in the global biotech landscape. As the U.S. also experiences a resurgence in biotech IPOs, the dynamics between these two markets will be crucial for future investments and growth in the sector.